Medical Management of Pulmonary Embolism

Outpatient therapy for select patients with PE can be initiated by administering the first dose in the emergency department or urgent care center.

There are specific selection criteria for outpatient treatment in patients with PE.

Warfarin dosing requires regular blood draws for INR monitoring and has a low bleeding risk compared to DOACs.

LMWH is commonly prescribed for long-term therapy due to its oral administration route.

DOACs require regular blood test monitoring similar to warfarin therapy.

Patients on warfarin do not need to consider dietary restrictions due to its low interaction with food.

Patients eligible for outpatient PE treatment should have serious comorbid conditions to qualify for this approach.

DOACs are more costly than warfarin for long-term anticoagulation therapy.

In select patients with PE, opioids are usually required for pain control during outpatient therapy initiation.

Warfarin has been the standard of care for long-term anticoagulation before the development of DOACs.

Which patients with PE are typically eligible for outpatient therapy initiation?

What is a common complication associated with warfarin therapy?

Which anticoagulant requires regular blood test monitoring for INR levels?

What is the ideal agent for outpatient administration in select PE patients?

What is a potential advantage of DOACs over warfarin for long-term anticoagulation therapy?

Why is LMWH usually not prescribed for long-term therapy in pulmonary embolism?